Faron Pharmaceuticals expands R&D strategy for Clevegen
Posted: 26 May 2016 | Victoria White, Digital Content Producer | No comments yet
Faron aims to extend the range of Clevegen indications through a technology platform called “Tumour Immunity Enabling Technology”, or TIET…
Faron’s Board of Directors has expanded the development strategy for Clevegen, the company’s novel cancer immunotherapy drug candidate.
Faron recently filed patents which have opened up new application opportunities for Clevegen in conditions where removal of suppression of local or systemic immunity is desirable.
Faron will now aim to extend the range of Clevegen indications through a technology platform called “Tumour Immunity Enabling Technology”, or TIET, which can be used alone or in combination with other immune checkpoint molecules. The Directors believe that Clevegen’s ability to convert pro-tumoural M2 macrophages to pro-inflammatory M1 macrophages could help the human body’s own immune system to combat cancer and significantly differentiates it from competing products. At the same time, the removal of immune suppression caused by M2 macrophages could provide a significant boost to the efficacy of other immune checkpoint molecules already in use or under development.
Leveraging the TIET technology platform
Faron intends to develop Clevegen in-house for immune dependent cancers such as hepatocellular carcinoma and other cancers known to depend on tumour associated macrophages. In addition the strategic decision by Faron to leverage the TIET technology platform may allow licensing opportunities and wider use of Clevegen as part of combination cancer therapies, maximising the value to cancer patients.
Commenting on the news, Dr Markku Jalkanen, CEO of Faron, said: “We have made significant progress with Clevegen this Spring, culminating in development of the new TIET technology platform. We will intensify our efforts in commercialising the TIET technology globally while also initiating our own cancer treatment programme.”
The TIET technology could significantly enhance lymphocyte activation programmes enabling them to be more effective in their fight against cancer cells, making TIET attractive to potential collaborators and licensing partners. Faron was granted €1.5 million funding from Tekes, the Finnish Funding Agency for Innovation, in December 2015 to progress the preclinical development of Clevegen.